| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ce77af986e4824cb05a336d649405d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 |
| filingDate |
2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c32672d24bbeea01b42388d0d710aa82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd2adfe26e9c838607fccf8919acca3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4278f58863df2b77c0f6f0c7ae5557ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f8f9e345678c3db09b042f243817ef1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f146b78db99f6862028efe8176eb5e85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b35c528b07a0a4515aab597267a3fe43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe5907ca70a28086652c3959737f970f |
| publicationDate |
2018-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10023583-B2 |
| titleOfInvention |
Bicyclic pyridine compound |
| abstract |
The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(bi-cyclic pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition. |
| priorityDate |
2015-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |